# A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

> **NCT03492697** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 12 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** PF-06882961 Immediate Release Tablet
- **DRUG:** PF-06882961 Controlled Release Tablet (long)
- **DRUG:** PF-06882961 Controlled Release Tablet (short)
- **DRUG:** PF-06882961 Immediate Release Solution

## Key facts

- **NCT ID:** NCT03492697
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-30
- **Primary completion:** 2018-07-18
- **Final completion:** 2018-07-18
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2018-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03492697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03492697, "A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03492697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*